See more : Tainan Enterprise (Cayman) Co., Limited (5906.TW) Income Statement Analysis – Financial Results
Complete financial analysis of CareDx, Inc (CDNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CareDx, Inc, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- One Equity Partners Open Water I Corp. (OEPW) Income Statement Analysis – Financial Results
- Shimmick Corporation Common Stock (SHIM) Income Statement Analysis – Financial Results
- Guangdong Jushen Logistics Co., Ltd. (001202.SZ) Income Statement Analysis – Financial Results
- ALBERT Inc. (3906.T) Income Statement Analysis – Financial Results
- TMC the metals company Inc. (TMCWW) Income Statement Analysis – Financial Results
CareDx, Inc (CDNA)
About CareDx, Inc
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 280.32M | 321.79M | 296.40M | 192.19M | 127.07M | 76.57M | 48.32M | 40.63M | 28.14M | 27.31M | 22.10M | 20.45M |
| Cost of Revenue | 102.00M | 112.21M | 97.39M | 63.12M | 45.46M | 32.99M | 21.37M | 21.12M | 10.27M | 8.54M | 9.08M | 7.93M |
| Gross Profit | 178.33M | 209.58M | 199.01M | 129.08M | 81.61M | 43.58M | 26.95M | 19.51M | 17.87M | 18.77M | 13.02M | 12.52M |
| Gross Profit Ratio | 63.61% | 65.13% | 67.14% | 67.16% | 64.23% | 56.92% | 55.78% | 48.02% | 63.50% | 68.72% | 58.92% | 61.22% |
| Research & Development | 81.87M | 90.39M | 76.53M | 48.94M | 30.71M | 14.51M | 12.39M | 12.39M | 9.33M | 3.85M | 3.18M | 4.75M |
| General & Administrative | 117.87M | 100.40M | 74.96M | 48.81M | 36.54M | 21.96M | 18.91M | 20.73M | 12.25M | 8.44M | 4.81M | 4.69M |
| Selling & Marketing | 83.33M | 96.03M | 77.25M | 53.86M | 38.89M | 21.67M | 12.81M | 11.17M | 8.35M | 6.47M | 5.89M | 5.42M |
| SG&A | 201.20M | 196.42M | 152.21M | 102.66M | 75.43M | 43.63M | 31.72M | 31.89M | 20.60M | 14.91M | 10.70M | 10.11M |
| Other Expenses | 98.62M | -2.87M | -2.63M | -4.81M | -719.00K | -178.00K | -1.49M | -1.92M | -188.00K | 147.00K | -536.00K | -14.00K |
| Operating Expenses | 381.69M | 286.81M | 228.73M | 146.79M | 106.15M | 58.14M | 44.11M | 44.28M | 29.93M | 18.75M | 13.88M | 14.86M |
| Cost & Expenses | 483.69M | 399.02M | 326.12M | 209.91M | 151.60M | 91.13M | 65.48M | 65.40M | 40.20M | 27.30M | 22.96M | 22.79M |
| Interest Income | 11.87M | 3.76M | 160.00K | 271.00K | 985.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.76M | 0.00 | 271.00K | 0.00 | 3.70M | 5.86M | 1.86M | 1.59M | 2.12M | 2.15M | 2.70M |
| Depreciation & Amortization | 19.82M | 16.01M | 11.89M | 9.54M | 5.52M | 4.22M | 3.76M | 2.92M | 796.00K | 512.00K | 663.00K | 1.07M |
| EBITDA | -89.66M | -61.22M | -17.84M | -10.21M | -19.01M | -11.36M | -14.61M | -17.85M | -11.26M | 523.00K | -194.00K | -1.27M |
| EBITDA Ratio | -31.98% | -24.03% | -10.06% | -8.44% | -19.56% | -19.25% | -38.59% | -65.68% | -43.29% | -4.50% | -0.88% | -6.21% |
| Operating Income | -203.36M | -77.23M | -29.73M | -17.72M | -24.53M | -15.58M | -20.29M | -37.33M | -11.93M | 1.25M | -857.00K | -2.34M |
| Operating Income Ratio | -72.55% | -24.00% | -10.03% | -9.22% | -19.31% | -20.35% | -42.00% | -91.88% | -42.40% | 4.58% | -3.88% | -11.45% |
| Total Other Income/Expenses | 13.22M | 997.00K | -2.36M | 2.78M | 585.00K | -32.64M | -36.98M | -4.03M | -1.78M | -1.97M | -2.69M | -2.72M |
| Income Before Tax | -190.14M | -76.23M | -32.09M | -19.75M | -23.95M | -48.22M | -57.27M | -41.36M | -13.71M | -719.00K | -3.54M | -5.06M |
| Income Before Tax Ratio | -67.83% | -23.69% | -10.83% | -10.28% | -18.85% | -62.97% | -118.51% | -101.80% | -48.70% | -2.63% | -16.03% | -24.74% |
| Income Tax Expense | 141.00K | 379.00K | -1.43M | -1.04M | -1.98M | -1.43M | -1.71M | -1.61M | 665.00K | -1.50M | 2.15M | 2.70M |
| Net Income | -190.28M | -76.61M | -30.66M | -18.71M | -21.97M | -46.76M | -55.47M | -39.47M | -13.71M | 781.00K | -3.54M | -5.06M |
| Net Income Ratio | -67.88% | -23.81% | -10.34% | -9.74% | -17.29% | -61.06% | -114.79% | -97.14% | -48.70% | 2.86% | -16.03% | -24.74% |
| EPS | -3.54 | -1.44 | -0.59 | -0.40 | -0.52 | -1.31 | -2.38 | -2.39 | -1.16 | 0.13 | -0.48 | -0.69 |
| EPS Diluted | -3.54 | -1.44 | -0.59 | -0.40 | -0.52 | -1.31 | -2.38 | -2.39 | -1.16 | 0.10 | -0.48 | -0.69 |
| Weighted Avg Shares Out | 53.76M | 53.32M | 52.24M | 46.48M | 42.15M | 35.64M | 23.31M | 16.50M | 11.82M | 5.82M | 7.37M | 7.37M |
| Weighted Avg Shares Out (Dil) | 53.76M | 53.32M | 52.24M | 46.48M | 42.15M | 35.64M | 23.33M | 16.50M | 11.86M | 9.28M | 7.37M | 7.37M |
Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?
Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know
After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA)
Are Medical Stocks Lagging CareDx (CDNA) This Year?
CareDx to Participate in Upcoming Investor Conferences
CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
CareDx, JD.com And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
CareDx Reports Preliminary Financial Results for Third Quarter 2024
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
Source: https://incomestatements.info
Category: Stock Reports